Patients with symptomatic severe aortic stenosis undergoing CoreValve or Evolut TAVI have better 5-year bioprosthetic valve ...

The following is a summary of "Transcatheter Aortic Valve Replacement Beyond Severe Aortic Stenosis: JACC State-of-the-Art Review," published in the March 2025 issue of the Journal of the American ...

A novel therapeutic showed significant promise in slowing aortic valve calcification, potentially extending time until or eliminating need for transcatheter or surgical intervention for stenosis, ...

Those who were eligible, had an aortic valve annulus area of ≤430mm as per the computed tomography measurements, and ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers at Mayo Clinic are exploring the use of a new drug called ...

Early surgical or transcatheter aortic valve replacement is not typically recommended for severe aortic stenosis in the ...

It ultimately slows progression of that valve calcium and then subsequently ... eventually be an option for most patients with documented aortic stenosis, even those with bicuspid and tricuspid ...

Krems, Austria – (March 12, 2025) – Recent research from Karl Landsteiner University of Health Sciences (KL Krems) provides important new insights into how aortic valve size is associated with the ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to ...

Aortic valve stenosis (AVS) is a major health issue, impacting over 1.5 million Americans and millions more worldwide. Researchers at the Mayo Clinic are investigating a new drug, ataciguat ...